知搜-全球专利检索

  1. 登录
  2. 注册

搜索结果

73 条记录 (耗时 0.025 秒)

    METHOD OF USING AN ANTI-CD137 ANTIBODY AS AN AGENT FOR RADIOIMMUNOTHERAPY OR RADIOIMMUNODETECTION
    1.
    发明申请
    METHOD OF USING AN ANTI-CD137 ANTIBODY AS AN AGENT FOR RADIOIMMUNOTHERAPY OR RADIOIMMUNODETECTION 审中-公开
    使用抗CD137抗体作为放射免疫疗法或放射免疫测定法的方法

    公开(公告)号：US20120058047A9

    公开(公告)日：2012-03-08

    申请号：US12713731

    申请日：2010-02-26

    申请人： Scott E. Strome ,  Daniel Schindler ,  Lieping Chen ,  Harry M. Meade ,  Yann Echelard

    发明人： Scott E. Strome ,  Daniel Schindler ,  Lieping Chen ,  Harry M. Meade ,  Yann Echelard

    IPC分类号： A61K51/00 ,  A61P35/02 ,  A61P35/04 ,  A61P35/00

    CPC分类号： A61K51/1096

    摘要： The current invention relates to the development and methods of use of a recombinant agonistic antibody anti-human CD137, and glycosylation variants thereof. These antibodies act as anti-cancer agents and/or immune modulators that are effective in shrinking solid tumors or other cancerous indications and preventing their recurrence. The types of cancer for which the contemplated antibody is effective in treating also include leukemia and lymphoma. In a preferred embodiment the recombinant antibodies of the current invention were produced in and purified from the milk of transgenic animals. In another preferred embodiment of the current invention the agonistic anti-CD137 antibodies of the invention can be conjugated to radionuclides for radioimmunodetection or radioimmunotherapeutic purposes, or conjugated to a toxin for enhanced therapeutic treatment of various cancers.

    摘要翻译： 本发明涉及重组激动抗体抗人CD137及其糖基化变体的开发和使用方法。 这些抗体作为有效减少实体瘤或其他癌症适应症并防止其复发的抗癌剂和/或免疫调节剂。 预期抗体对其治疗有效的癌症类型还包括白血病和淋巴瘤。 在优选的实施方案中，本发明的重组抗体在转基因动物的牛奶中制备并纯化。 在本发明的另一个优选实施方案中，本发明的激动性抗CD137抗体可以与放射性核素缀合以用于放射免疫检测或放射免疫治疗目的，或与毒素结合以增强各种癌症的治疗性治疗。

    METHOD OF USING AN ANTI-CD137 ANTIBODY AS AN AGENT FOR RADIOIMMUNOTHERAPY OR RADIOIMMUNODETECTION
    2.
    发明申请
    METHOD OF USING AN ANTI-CD137 ANTIBODY AS AN AGENT FOR RADIOIMMUNOTHERAPY OR RADIOIMMUNODETECTION 审中-公开
    使用抗CD137抗体作为放射免疫疗法或放射免疫测定法的方法

    公开(公告)号：US20110104049A1

    公开(公告)日：2011-05-05

    申请号：US12713731

    申请日：2010-02-26

    申请人： Scott E. Strome ,  Daniel Schindler ,  Lieping Chen ,  Harry M. Meade ,  Yann Echelard

    发明人： Scott E. Strome ,  Daniel Schindler ,  Lieping Chen ,  Harry M. Meade ,  Yann Echelard

    IPC分类号： A61K51/00 ,  A61P35/00 ,  A61P35/02 ,  A61P35/04

    CPC分类号： A61K51/1096

    摘要： The current invention relates to the development and methods of use of a recombinant agonistic antibody anti-human CD137, and glycosylation variants thereof. These antibodies act as anti-cancer agents and/or immune modulators that are effective in shrinking solid tumors or other cancerous indications and preventing their recurrence. The types of cancer for which the contemplated antibody is effective in treating also include leukemia and lymphoma. In a preferred embodiment the recombinant antibodies of the current invention were produced in and purified from the milk of transgenic animals. In another preferred embodiment of the current invention the agonistic anti-CD137 antibodies of the invention can be conjugated to radionuclides for radioimmunodetection or radioimmunotherapeutic purposes, or conjugated to a toxin for enhanced therapeutic treatment of various cancers.

    摘要翻译： 本发明涉及重组激动抗体抗人CD137及其糖基化变体的开发和使用方法。 这些抗体作为有效减少实体瘤或其他癌症适应症并防止其复发的抗癌剂和/或免疫调节剂。 预期抗体对其治疗有效的癌症类型还包括白血病和淋巴瘤。 在优选的实施方案中，本发明的重组抗体在转基因动物的牛奶中制备并纯化。 在本发明的另一个优选实施方案中，本发明的激动性抗CD137抗体可以与放射性核素缀合以用于放射免疫检测或放射免疫治疗目的，或与毒素结合以增强各种癌症的治疗性治疗。

    Detection of antibodies specific for B7-H1 in subjects with diseases or pathological conditions mediated by activated T cells
    3.
    发明授权
    Detection of antibodies specific for B7-H1 in subjects with diseases or pathological conditions mediated by activated T cells 有权
    检测受活化T细胞介导的疾病或病理状况受试者B7-H1特异性抗体

    公开(公告)号：US07449300B2

    公开(公告)日：2008-11-11

    申请号：US10719477

    申请日：2003-11-21

    申请人： Lieping Chen ,  Scott E. Strome

    发明人： Lieping Chen ,  Scott E. Strome

    IPC分类号： G01N33/53

    CPC分类号： C07K16/2827 ,  A61K2039/505 ,  C07K2317/74

    摘要： The invention provides methods of removing B7-H1-specific antibodies from a body fluid (e.g., blood), methods of diagnosing and treating diseases and pathological conditions mediated by activated T cells, methods for screening for compounds that inhibit binding of a B7-H1-specific antibody to B7-H1, and methods of designing compounds that inhibit binding of a B7-H1-specific antibody to B7-H1.

    摘要翻译： 本发明提供从体液（例如血液）中除去B7-H1特异性抗体的方法，诊断和治疗由活化的T细胞介导的疾病和病理状况的方法，筛选抑制B7-H1结合的化合物的方法 B7-H1的特异性抗体，以及设计抑制B7-H1特异性抗体与B7-H1结合的化合物的方法。